Loading...

Diagnostic and Therapeutic Center of Athens HYGEIA

DB:DTM
Snowflake Description

Solid track record and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
DTM
DB
€290M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Diagnostic and Therapeutic Center of Athens HYGEIA SA operates as a subsidiary of Hellenic Healthcare Single-Member Holdings SA. The last earnings update was 203 days ago. More info.


Add to Portfolio Compare Print
DTM Share Price and Events
7 Day Returns
0%
DB:DTM
0.2%
DE Healthcare
0.5%
DE Market
1 Year Returns
10.2%
DB:DTM
-15.9%
DE Healthcare
-8.1%
DE Market
DTM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Diagnostic and Therapeutic Center of Athens HYGEIA (DTM) 0% -0.2% 0% 10.2% 527.3% 129%
DE Healthcare 0.2% 10% 19.5% -15.9% -13.4% 47.7%
DE Market 0.5% 2.6% 6.1% -8.1% 11.6% 14.7%
1 Year Return vs Industry and Market
  • DTM outperformed the Healthcare industry which returned -15.9% over the past year.
  • DTM outperformed the Market in Germany which returned -8.1% over the past year.
Price Volatility
DTM
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Diagnostic and Therapeutic Center of Athens HYGEIA undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Diagnostic and Therapeutic Center of Athens HYGEIA to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Diagnostic and Therapeutic Center of Athens HYGEIA.

DB:DTM Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 14.8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:DTM
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 15%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.73
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.727 (1 + (1- 29%) (44.27%))
0.97
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.97
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.97 * 14.99%)
14.77%

Discounted Cash Flow Calculation for DB:DTM using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Diagnostic and Therapeutic Center of Athens HYGEIA is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:DTM DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 14.77%)
2019 37.21 Est @ 78.71% 32.43
2020 57.74 Est @ 55.16% 43.84
2021 80.08 Est @ 38.68% 52.98
2022 101.82 Est @ 27.15% 58.69
2023 121.24 Est @ 19.07% 60.89
2024 137.50 Est @ 13.42% 60.18
2025 150.51 Est @ 9.46% 57.40
2026 160.58 Est @ 6.69% 53.36
2027 168.21 Est @ 4.75% 48.71
2028 173.93 Est @ 3.39% 43.88
Present value of next 10 years cash flows €512.36
DB:DTM DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €173.93 × (1 + 0.23%) ÷ (14.77% – 0.23%)
€1,199.15
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €1,199.15 ÷ (1 + 14.77%)10
€302.54
DB:DTM Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €512.36 + €302.54
€814.89
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €814.89 / 305.73
€2.67
DB:DTM Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:DTM represents 0.99053x of ATSE:HYGEIA
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.99053x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 2.67 x 0.99053
€2.64
Value per share (EUR) From above. €2.64
Current discount Discount to share price of €0.94
= -1 x (€0.94 - €2.64) / €2.64
64.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Diagnostic and Therapeutic Center of Athens HYGEIA is available for.
Intrinsic value
>50%
Share price is €0.94 vs Future cash flow value of €2.64
Current Discount Checks
For Diagnostic and Therapeutic Center of Athens HYGEIA to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Diagnostic and Therapeutic Center of Athens HYGEIA's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Diagnostic and Therapeutic Center of Athens HYGEIA's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Diagnostic and Therapeutic Center of Athens HYGEIA's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Diagnostic and Therapeutic Center of Athens HYGEIA's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:DTM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in EUR €0.05
ATSE:HYGEIA Share Price ** ATSE (2019-04-03) in EUR €0.95
Germany Healthcare Industry PE Ratio Median Figure of 10 Publicly-Listed Healthcare Companies 40.55x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.34x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Diagnostic and Therapeutic Center of Athens HYGEIA.

DB:DTM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ATSE:HYGEIA Share Price ÷ EPS (both in EUR)

= 0.95 ÷ 0.05

20.31x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Diagnostic and Therapeutic Center of Athens HYGEIA is good value based on earnings compared to the DE Healthcare industry average.
  • Diagnostic and Therapeutic Center of Athens HYGEIA is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Diagnostic and Therapeutic Center of Athens HYGEIA's expected growth come at a high price?
Raw Data
DB:DTM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 20.31x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Germany Healthcare Industry PEG Ratio Median Figure of 7 Publicly-Listed Healthcare Companies 1.6x
Germany Market PEG Ratio Median Figure of 273 Publicly-Listed Companies 1.49x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Diagnostic and Therapeutic Center of Athens HYGEIA, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Diagnostic and Therapeutic Center of Athens HYGEIA's assets?
Raw Data
DB:DTM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in EUR €0.43
ATSE:HYGEIA Share Price * ATSE (2019-04-03) in EUR €0.95
Germany Healthcare Industry PB Ratio Median Figure of 12 Publicly-Listed Healthcare Companies 1.5x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:DTM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ATSE:HYGEIA Share Price ÷ Book Value per Share (both in EUR)

= 0.95 ÷ 0.43

2.22x

* Primary Listing of Diagnostic and Therapeutic Center of Athens HYGEIA.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Diagnostic and Therapeutic Center of Athens HYGEIA is overvalued based on assets compared to the DE Healthcare industry average.
X
Value checks
We assess Diagnostic and Therapeutic Center of Athens HYGEIA's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Diagnostic and Therapeutic Center of Athens HYGEIA has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Diagnostic and Therapeutic Center of Athens HYGEIA expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Diagnostic and Therapeutic Center of Athens HYGEIA has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
2.8%
Expected Healthcare industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Diagnostic and Therapeutic Center of Athens HYGEIA expected to grow at an attractive rate?
  • Unable to compare Diagnostic and Therapeutic Center of Athens HYGEIA's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Diagnostic and Therapeutic Center of Athens HYGEIA's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Diagnostic and Therapeutic Center of Athens HYGEIA's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:DTM Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 2.8%
Germany Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 5.4%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:DTM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:DTM Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-06-30 212 27 14
2018-03-31 209 18 12
2017-12-31 206 9 10
2017-06-30 197 11 8
2017-03-31 201 10 6
2016-12-31 206 8 4
2016-09-30 227 4 -15
2016-06-30 222 3 -21
2016-03-31 222 12 -24
2015-12-31 220 17 -27
2015-09-30 219 15 -16

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Diagnostic and Therapeutic Center of Athens HYGEIA is high growth as no earnings estimate data is available.
  • Unable to determine if Diagnostic and Therapeutic Center of Athens HYGEIA is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:DTM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Diagnostic and Therapeutic Center of Athens HYGEIA Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:DTM Past Financials Data
Date (Data in EUR Millions) EPS *
2018-06-30 0.05
2018-03-31 0.04
2017-12-31 0.03
2017-06-30 0.03
2017-03-31 0.02
2016-12-31 0.01
2016-09-30 -0.05
2016-06-30 -0.07
2016-03-31 -0.08
2015-12-31 -0.09
2015-09-30 -0.05

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Diagnostic and Therapeutic Center of Athens HYGEIA will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine whether Diagnostic and Therapeutic Center of Athens HYGEIA is trading at Diagnostic and Therapeutic Center of Athens HYGEIA'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  2. Diagnostic and Therapeutic Center of Athens HYGEIA's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Diagnostic and Therapeutic Center of Athens HYGEIA's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Diagnostic and Therapeutic Center of Athens HYGEIA's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Diagnostic and Therapeutic Center of Athens HYGEIA has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Diagnostic and Therapeutic Center of Athens HYGEIA performed over the past 5 years?

  • Diagnostic and Therapeutic Center of Athens HYGEIA's last earnings update was 203 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Diagnostic and Therapeutic Center of Athens HYGEIA's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Diagnostic and Therapeutic Center of Athens HYGEIA has delivered over 20% year on year earnings growth in the past 5 years.
  • Diagnostic and Therapeutic Center of Athens HYGEIA's 1-year earnings growth exceeds its 5-year average (85.6% vs 65.2%)
  • Diagnostic and Therapeutic Center of Athens HYGEIA's earnings growth has exceeded the DE Healthcare industry average in the past year (85.6% vs 3%).
Earnings and Revenue History
Diagnostic and Therapeutic Center of Athens HYGEIA's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Diagnostic and Therapeutic Center of Athens HYGEIA Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:DTM Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 211.88 14.30 21.12
2018-03-31 208.93 11.98 20.85
2017-12-31 205.97 9.66 20.57
2017-06-30 196.93 7.70 17.94
2017-03-31 201.41 5.94 18.97
2016-12-31 205.89 4.17 20.01
2016-09-30 227.04 -15.14 24.63
2016-06-30 222.45 -20.55 24.92
2016-03-31 221.98 -23.99 25.66
2015-12-31 220.31 -26.56 26.15
2015-09-30 219.16 -16.25 27.12
2015-06-30 216.99 -14.87 28.66
2015-03-31 216.73 -18.54 27.27
2014-12-31 217.54 -18.75 28.70
2014-09-30 197.68 -38.33 27.08
2014-06-30 198.04 -40.43 27.15
2014-03-31 199.55 -39.04 27.13
2013-12-31 203.66 -38.10 26.73
2013-09-30 229.89 -111.36 26.76
2013-06-30 235.33 -109.44 27.15
2013-03-31 236.80 -108.35 27.79
2012-12-31 237.95 -110.55 28.66
2012-09-30 231.28 -16.61 32.72
2012-06-30 232.69 -20.86 33.10

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Diagnostic and Therapeutic Center of Athens HYGEIA has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Diagnostic and Therapeutic Center of Athens HYGEIA used its assets more efficiently than the DE Healthcare industry average last year based on Return on Assets.
  • Diagnostic and Therapeutic Center of Athens HYGEIA has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Diagnostic and Therapeutic Center of Athens HYGEIA's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Diagnostic and Therapeutic Center of Athens HYGEIA has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Diagnostic and Therapeutic Center of Athens HYGEIA's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Diagnostic and Therapeutic Center of Athens HYGEIA's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Diagnostic and Therapeutic Center of Athens HYGEIA is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Diagnostic and Therapeutic Center of Athens HYGEIA's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Diagnostic and Therapeutic Center of Athens HYGEIA's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Diagnostic and Therapeutic Center of Athens HYGEIA Company Filings, last reported 9 months ago.

DB:DTM Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 131.24 128.59 13.54
2018-03-31 131.24 128.59 13.54
2017-12-31 120.85 131.59 11.15
2017-06-30 127.32 155.92 5.61
2017-03-31 127.32 155.92 5.61
2016-12-31 120.70 157.93 14.90
2016-09-30 120.70 157.93 14.90
2016-06-30 124.00 160.30 4.31
2016-03-31 124.00 160.30 4.31
2015-12-31 119.74 159.82 14.29
2015-09-30 137.35 161.91 12.97
2015-06-30 144.44 162.54 8.18
2015-03-31 145.70 162.37 4.73
2014-12-31 146.23 165.99 4.81
2014-09-30 160.21 163.77 11.33
2014-06-30 166.14 164.39 12.51
2014-03-31 171.20 177.95 4.49
2013-12-31 172.01 178.74 25.82
2013-09-30 196.46 181.07 19.50
2013-06-30 204.76 181.19 19.43
2013-03-31 211.31 181.36 20.84
2012-12-31 214.89 185.39 24.38
2012-09-30 338.38 201.57 32.21
2012-06-30 345.94 202.16 34.99
  • Diagnostic and Therapeutic Center of Athens HYGEIA's level of debt (98%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (88.5% vs 98% today).
  • Debt is well covered by operating cash flow (20.8%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 3.3x coverage).
X
Financial health checks
We assess Diagnostic and Therapeutic Center of Athens HYGEIA's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Diagnostic and Therapeutic Center of Athens HYGEIA has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Diagnostic and Therapeutic Center of Athens HYGEIA's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Diagnostic and Therapeutic Center of Athens HYGEIA dividends.
If you bought €2,000 of Diagnostic and Therapeutic Center of Athens HYGEIA shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Diagnostic and Therapeutic Center of Athens HYGEIA's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Diagnostic and Therapeutic Center of Athens HYGEIA's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:DTM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Germany Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.6%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:DTM Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2011-11-10 0.000 0.000
2011-08-23 0.000 0.000
2011-03-28 0.000 0.000
2010-11-23 0.150 23.537
2010-08-27 0.150 19.129
2010-05-17 0.150 13.802
2009-04-14 0.170 9.623

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Diagnostic and Therapeutic Center of Athens HYGEIA has not reported any payouts.
  • Unable to verify if Diagnostic and Therapeutic Center of Athens HYGEIA's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Diagnostic and Therapeutic Center of Athens HYGEIA's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Diagnostic and Therapeutic Center of Athens HYGEIA has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Diagnostic and Therapeutic Center of Athens HYGEIA's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Diagnostic and Therapeutic Center of Athens HYGEIA afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Diagnostic and Therapeutic Center of Athens HYGEIA has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Diagnostic and Therapeutic Center of Athens HYGEIA's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Andreas Kartapanis
CEO Bio

Mr. Andreas Kartapanis serves as the Chief Executive Officer of Diagnostic & Therapeutic Center of Athens Hygeia S.A. Mr. Kartapanis has been Managing Director of MITERA SA since January 12, 2016. Mr. Kartapanis served as General Manager at Diagnostic & Therapeutic Center of Athens Hygeia S.A. Mr. Kartapanis served as an Administrative Director of HYGEIA SA. Mr. Kartapanis served as Managing Director at MITERA S.A. until October 27, 2015. He serves as Director of MITERA S.A. He serves as Executive Director at Diagnostic & Therapeutic Center of Athens Hygeia S.A. He is a graduate of the Athens University of Economics Management and Business Administration Department.

CEO Compensation
  • Insufficient data for Andreas to compare compensation growth.
  • Insufficient data for Andreas to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

Andreas Kartapanis

TITLE
CEO & Executive Director

N. Christeas

TITLE
Co-Founder

EL Kelepouri

TITLE
Chief Financial Officer

Dimitrios-Eleftherios Mantzavinos

TITLE
Group CFO & Executive Director

Charilaos Chiniadis

TITLE
Technical Support Director
TENURE
12.3 yrs

Marina Mantzourani

TITLE
Manager of the Investor Relations & Shareholders Service Department

Despoina Mitropoulou

TITLE
Human Resources Director

Nikolaos Lekakis

TITLE
Group Financial Controller

Spyridon Kosmas

TITLE
Group Deputy Chief Financial Officer

Ilias Politakis

TITLE
Secretary of the Scientific Board & Member of Scientific Board
Board of Directors Tenure

Average tenure of the Diagnostic and Therapeutic Center of Athens HYGEIA board of directors in years:

2.1
Average Tenure
  • The average tenure for the Diagnostic and Therapeutic Center of Athens HYGEIA board of directors is less than 3 years, this suggests a new board.
Board of Directors

Athanasios Papanikolaou

TITLE
Chairman
TENURE
2.3 yrs

Andreas Kartapanis

TITLE
CEO & Executive Director

Georgios Politis

TITLE
Vice Chairman

Dimitrios-Eleftherios Mantzavinos

TITLE
Group CFO & Executive Director

Ilias Politakis

TITLE
Secretary of the Scientific Board & Member of Scientific Board

Georgios Zacharopoulos

TITLE
President of the Scientific Board & Non-Executive Director

Athanasios Christopoulos

TITLE
Independent Non-Executive Director
TENURE
2.1 yrs

Stylianos Konstantinidis

TITLE
Vice Chairman of Scientific Board
TENURE
0.1 yrs

Anastasios Kyprianidis

TITLE
Non Executive Director

Gerasimos Alivizatos

TITLE
Member of the Scientific Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Diagnostic and Therapeutic Center of Athens HYGEIA's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Diagnostic and Therapeutic Center of Athens HYGEIA has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Diagnostic and Therapeutic Center of Athens HYGEIA SA operates as a subsidiary of Hellenic Healthcare Single-Member Holdings SA.

Details
Name: Diagnostic and Therapeutic Center of Athens HYGEIA SA
DTM
Exchange: DB
Founded: 1970
€290,445,814
305,732,436
Website: http://www.hygeia.gr
Address: Diagnostic and Therapeutic Center of Athens HYGEIA SA
4, Erythrou Stavrou Street and Kifisias Avenue,
Marousi,
Athens,
151 23,
Greece
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ATSE HYGEIA Ordinary Registered Shares The Athens Stock Exchange GR EUR 07. Jun 2002
DB DTM Ordinary Registered Shares Deutsche Boerse AG DE EUR 07. Jun 2002
LSE 0MVT Ordinary Registered Shares London Stock Exchange GB EUR 07. Jun 2002
Number of employees
Current staff
Staff numbers
2,656
Diagnostic and Therapeutic Center of Athens HYGEIA employees.
Industry
Health Care Facilities
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/10 22:15
End of day share price update: 2019/04/03 00:00
Last earnings filing: 2018/09/19
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.